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ABSTRACT
Triple negative breast cancer (TNBC) is characterized by a poorly differentiated 
phenotype and limited treatment options. Aberrant epigenetics in this subtype 
represent a potential therapeutic opportunity, but a better understanding of the 
mechanisms contributing to the TNBC pathogenesis is required. The SIN3 molecular 
scaffold performs a critical role in multiple cellular processes, including epigenetic 
regulation, and has been identified as a potential therapeutic target. Using a 
competitive peptide corresponding to the SIN3 interaction domain of MAD (Tat-
SID), we investigated the functional consequences of selectively blocking the paired 
amphipathic α-helix (PAH2) domain of SIN3. Here, we report the identification of 
the SID-containing adaptor PF1 as a factor required for maintenance of the TNBC 
stem cell phenotype and epithelial-to-mesenchymal transition (EMT). Tat-SID 
peptide blocked the interaction between SIN3A and PF1, leading to epigenetic 
modulation and transcriptional downregulation of TNBC stem cell and EMT markers. 
Importantly, Tat-SID treatment also led to a reduction in primary tumor growth and 
disseminated metastatic disease in vivo. In support of these findings, knockdown of 
PF1 expression phenocopied treatment with Tat-SID both in vitro and in vivo. These 
results demonstrate a critical role for a complex containing SIN3A and PF1 in TNBC 
and provide a rational for its therapeutic targeting.
INTRODUCTION
Breast cancer is a complex and heterogeneous 
disease with diverse molecular and clinical phenotypes. 
The molecular subtyping of breast cancer is broadly based 
on the status of estrogen receptor (ER), progesterone 
receptor (PR) and epidermal growth factor receptor 2 
(Her2) [1]. Triple negative breast cancer (TNBC), an 
aggressive subtype comprising 15-20% of breast cancer 
incidences is associated with early recurrence, shorter 
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median survival time after relapse and development 
of chemoresistant disease. [2]. Despite considerable 
therapeutic advances for ER-positive and Her2-positive 
breast cancers, targeted drugs are not yet clinically 
available for TNBC [2] and their future development will 
require a better understanding of the biology of TNBC 
tumors.
Although 70% of TNBC tumors phenotypically 
resemble basal-like breast cancer and genetic mutations 
at the BRCA1 and TP53 loci are frequently observed 
[3], molecular profiling suggests that TNBC is in fact a 
heterogeneous entity. This heterogeneity in TNBC (and 
cancer in general), cannot be explained by classic genetics 
alone and it has become increasingly clear that aberrant 
epigenetics play a significant role [4]. Tumor-associated 
changes in methylation of DNA or core histones H3 and 
H4, resulting in deregulated expression of important 
TNBC genes including ESR1, CDH1, MUC1 and BRCA1, 
have been attributed to development of TNBC [4]. 
Aberrant epigenetics also underpin the cellular plasticity 
required for the functional adaptation of cancer cells to 
their environment, including epithelial-to-mesenchymal 
transition (EMT) that is necessary for the tumor invasion-
metastasis cascade and acquisition or maintenance of stem 
cell-like traits of tumor-initiating cancer stem cells (CSCs) 
[5]. The reversible nature of epigenetic changes, however, 
also presents opportunities for therapeutic intervention 
and numerous “epidrugs”, including histone deacetylase 
inhibitors and demethylating agents, are being evaluated 
in TNBC [6-9].
Epigenetic reconfiguration in cancer cells is brought 
about by aberrant recruitment of chromatin modifying 
complexes, including the SIN3 transcription complex, 
that possess diverse chromatin modifying enzymatic 
activities. Mammalian SIN3 (SIN3A and SIN3B), via its 
multiple protein-protein interaction domains, serves as a 
scaffold bridging together sequence-specific DNA binding 
transcription factors and various chromatin regulators [10, 
11]. Both SIN3A and SIN3B are characterized by a unique 
arrangement of four paired amphipathic α-helix (PAH1-
PAH4) motifs. While they share sequence homology, 
the different PAH domains mediate specific SIN3A and 
SIN3B interactions, with the second PAH repeat (PAH2) 
reported to bind a functionally diverse group of proteins, 
including the MAD family of repressors, that contain a 
motif known as a SIN3 interaction domain (SID) [12]. 
The SIN3 complex has important regulatory functions 
in cell proliferation, development and differentiation and 
its aberrant recruitment is implicated in breast cancer 
pathogenesis [13-15].
Our previous work has suggested that blocking 
specific interactions of the SIN3 PAH2 domain could 
represent a novel therapeutic approach in TNBC [15, 
16]. Using a peptide corresponding to the SID domain of 
MAD (Tat-SID) we sought to characterize the phenotypic 
consequences of interfering with SIN3 function and 
identify candidate PAH2-interacting factors in TNBC. 
Here, we report the identification of the SID-containing 
adaptor protein PF1 (PHF12), which is expressed from 
a locus amplified in breast cancer [17, 18], as a factor 
required for EMT and cancer stem cell maintenance in 
TNBC.
RESULTS
Tat-SID disrupts the interaction between SIN3A 
and a complex containing PF1, MRG15 and 
KDM5B
The PAH2 domain of SIN3 mediates interactions 
with a restricted subset of factors containing a conserved 
SIN3 interaction domain (SID) with homology to amino 
acids 5-24 of the prototypic PAH2-binding protein, the 
transcriptional repressor MAD [19-22]. In order to dissect 
the function of SIN3 PAH2 we used a 31-mer decoy 
peptide comprising amino acids 5-24 of MAD SID and 
the nuclear localization signal of HIV-1 Tat (Tat-SID: 
YGRKKRRQGGG-VRMNIQMLLEAADYLERRER), 
which results in increased nuclear accumulation of Tat-
SID decoy peptide with time irrespective of serum 
concentration (Figure 1A). We focused our investigation 
on the plant homeodomain (PHD)-containing protein 
PF1 (PHF12), which links SIN3 PAH2 to a chromatin-
modifying protein complex containing MRG15, LID 
(the Drosophila homolog of KDM5A/B) and EMSY [20, 
23-25] that has been implicated in breast cancer [26-30]. 
Consistent with our previous results demonstrating Tat-
SID-mediated disruption of the interaction between PAH2 
and SID-containing MAD [15] (Figure S1), both co-
immunoprecipitation and proximity ligation assay (PLA) 
showed that Tat-SID effectively blocked the SIN3A-PF1 
interaction in MDA-MB-231 cells (Figures 1B, 1C and 
S2A). In comparison to MAD, PF1 has been reported 
to bind to PAH2 with a 10-fold lower affinity [31] and 
we also found the amount of a peptide corresponding 
to the PF1-SID required to compete for binding to a 
FITC-labeled MAD probe to be 12-fold greater (IC50 = 
1.26 µM for MAD SID versus 15.59 µM for PF1 SID; 
Figure S2B). EMSY has also recently been identified as a 
binding partner for KDM5B [29], which prompted us to 
investigate the interaction between KDM5B and SIN3A. 
Supporting the notion that SID treatment could disrupt a 
functional complex, the interaction between SIN3A and 
KDM5B was also inhibited in a time- and concentration-
dependent manner (Figures 1D, 1E and S2C). A decrease 
in the association between SIN3A and MRG15 following 
Tat-SID treatment was also observed, although this effect 
was less pronounced and may be due to the presence of an 
additional MRG15 binding site in the histone interaction 
domain (HID) of SIN3 (Figure 1F) [23].
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Figure 1: Tat-SID disrupts interaction between SIN3A and a chromatin regulating protein complex containing PF1, 
MRG15 and KDM5B. A. Left, histograms showing cellular uptake of Tat-SID analyzed by flow cytometer in MDA-MB-231 cells 
treated with 1 µM FITC-conjugated Tat-SID for 2 h and 24 h in 1% (red), 2.5% (green), 5% (blue) and 10% (pink) serum. Black histogram 
represents untreated cells. Right, confocal images of MDA-MB-231 treated with 1 µM FITC-conjugated Tat-SID (green) and stained 
with nuclear stain DAPI (blue). Scale bars: 25 µm. B. IP-immunoblot analysis of MDA-MB-231 cells treated with 1 µM Tat-SID for 24 
h, immunoprecipitated with anti-Sin3A antibody and immunoblotted with anti-PF1 antibody (upper panel), or immunoprecipitated with 
anti-PF1 antibody and immunoblotted with anti-Sin3A antibody (lower panel). Input corresponds to 10% of the total protein used for 
immunoprecipitation. C. Quantification of proximity ligation assay (PLA) analyzing the interaction between SIN3A and PF1 in MDA-
MB-231 cells treated with 1 µM and 5 µM Tat-SID treatments respectively for 24 h (red) in comparison to Tat-Scr (grey). Tat-Scr versus 
1 µM Tat-SID, *, p = 0.0251; Tat-Scr versus 5 µM Tat-SID, *, p = 0.0217; p, unpaired t-test. D. IP-immunoblot analysis of MDA-MB-231 
cells treated with 1 µM Tat-SID for 24 h, immunoprecipitated with anti-Sin3A & anti-KDM5B antibodies and immunoblotted with anti-
KDM5B antibody (upper panel), or immunoprecipitated with anti-KDM5B & anti-Sin3A antibodies and immunoblotted with anti-Sin3A 
antibody (lower panel). Input corresponds to 20% and 5% of the total protein used for immunoprecipitation. E. Quantification of PLA 
analyzing the interaction between SIN3A and KDM5B in MDA-MB-231 cells treated with 1 (red) and 5 µM Tat-SID (blue) for different 
time points in comparison to 5 µM Tat-Scr (grey). Tat-Scr versus 1 µM Tat-SID 72 h, *, p = 0.0119; Tat-Scr versus 5 µM Tat-SID 72 h, *, p = 
0.0111; p, unpaired t-test. F. IP-immunoblot analysis of MDA-MB-231 cells treated with 1 µM Tat-SID for 24 h, immunoprecipitated with 
anti-Sin3A antibody and immunoblotted with anti-MRG15. Input corresponds to 10% of the total protein used for immunoprecipitation. 
Error bars represent mean ± SD (n = 3).
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Blocking SIN3-PAH2 interactions inhibits the 
EMT program in cancer cells
Consistent with our previous results obtained by 
stably expressing SID peptide [15], treatment with Tat-
SID led to a time-dependent increase in expression 
of CDH1 mRNA of greater than 3-fold and plasma 
membrane-associated E-cadherin became evident at 72 
h (Figure 2A). Similar results were observed for ERα 
with 4.5-fold increase in ESR1 expression and increased 
protein levels after 7 days of Tat-SID treatment (Figure 
2B). SID decoy was also found to induce re-expression 
of CDH1 and ESR1 in three additional TNBC lines, 
MDA-MB-157, 4T1 and MMTV-Myc (Figure S3A 
and S3B). To gain further insight into transcriptional 
reprogramming associated with Tat-SID treatment, we 
performed expression microarray analysis. Pathway 
analysis of these data identified regulation of EMT as 
one of the most significant pathways modulated in Tat-
SID treated cells compared to Tat-Scr (Table 1 and Tables 
S1-S3). Other pathways that were significantly regulated 
included cell migration/cell adhesion, cell proliferation 
and cell death and survival (Tables S2 and S4). Of note, 
Tat-SID treatment induced downregulation of important 
molecular markers of EMT such as FGFR2, FGFR4, 
TWIST1 and WNT5A (Table 1). Of these, Tat-SID induced 
down-regulation of FGFR2, FGFR4 and WNT5A were 
validated by qRT-PCR (Figure S4). Further evidence of 
Tat-SID-induced regulation of EMT was provided by the 
‘Upstream transcription factor analysis’ that predicted 
inhibition of TGFB1 (z score: -4.4), CTNNB1 ( β-catenin) 
(z score: -3.3), SMAD3 (z Score: -2.6) and SMAD4 (z 
score: -2.2), four major inducers of EMT (Tables S5 and 
S6). Other genes encoding relevant transcription factors 
predicted to be downregulated upon Tat-SID treatment 
included RARG, MAPK3 and E2F1, offering additional 
clues to the mechanisms underlying inhibition of cell 
proliferation and migration pathways (Table S2).
Figure 2: Tat-SID induces functional re-expression of epigenetically silenced ESR1 and CDH1. A. Left, qRT-PCR for 
expression of CDH1 mRNA in MDA-MB-231 cell untreated (grey) or treated (red) with 2.5 µM Tat-SID for the indicated time. Untreated 
versus Tat-SID 72 h, **, p = 0.0016; untreated versus Tat-SID 144 h, **, p = 0.0035; p, unpaired t-test. Right, confocal images of MDA-
MB-231 cell untreated or treated with 2.5 µM Tat-SID for 72 h and immunostained for CDH1 protein (green). Blue is the nuclear stain 
DAPI. Scale bar: 20 µm. B. Left, qRT-PCR for expression of ESR1 mRNA in MDA-MB-231 cell untreated (grey) or treated (red) with 2.5 
µM Tat-SID for the indicated time. Untreated versus Tat-SID 72 h, ***, p = 0.0002; untreated versus Tat-SID 144 h, ***, p = 0.0002; p, 
unpaired t-test. Right, immunoblot analysis of  ERα expression in MDA-MB-231 cells treated with Tat-Scr or Tat-SID for 7 days.
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Tat-SID treatment reduces global promoter H3K4 
trimethylation
To better understand the effect of Tat-SID on the 
epigenetic landscape of TNBC, we performed ChIP 
coupled with next-generation sequencing (ChIP-Seq) 
on H3K4me3 in MDA-MB-231 cells treated with Tat-
SID (1 μM and 2.5 μM). Instead of an expected increase 
in H3K4me3 we observed dose-dependent reduction 
in H3K4me3 at fewer than 10% of the genome-wide 
transcription start sites (TSS) of annotated genes (Figures 
3A, 3B, S5A and Table S7). Analysis of the ChIP-Seq 
data using SICER-df and Bedtools identified 124 (1 
μM Tat-SID) or 2313 gene promoters (2.5 μM Tat-SID) 
with significant promoter H3K4me3 reduction (FDR < 
1 X 10-15), in contrast to relatively few genes with 
H3K4me3 increase (FDR < 1 X 10-15) (Figure S5A and 
Table S7). Given that Tat-SID treatment perturbed the 
SIN3A-KDM5B interaction, we performed a comparison 
of Tat-SID target gene promoters with those known to 
be KDM5B targets [30]. Interestingly, we found that 
promoters with reduced H3K4me3 after treatment with 
Tat-SID were significantly enriched for KDM5B binding 
(p < 0.0001) (Figure S5B and S5C). These promoters 
included CD44, ITGA6 (CD49f) and SNAI2 (SLUG) that 
are known to regulate the mammary gland stem cell state 
(Figure 3C) [32]. ChIP-Seq analysis with Tat-SID peptide 
did not indicate significant epigenetic remodeling of H3K4 
trimethylation at the CDH1 and ESR1 promoters as found 
in our previous study [15]. However, in that study, SID 
peptide was expressed from a plasmid vector over a longer 
time period.
Tat-SID impairs invasive morphogenesis and 
induces anti-tumor effects
Tat-SID treatment of MDA-MB-231 3D cultures in 
basement membrane matrix that closely mimics the tumor 
microenvironment exerted a strong anti-invasive effect 
(Figure 4A) characterized by the presence of small (50-
100 µM diameter), non-invasive spherically organized 
colonies in contrast to the large (>200 µM average 
diameter) disorganized colonies with invasive projections 
observed with Tat-Scr control (Figure 4A). Although Tat-
SID treated colonies resembled acini-like spheroids with 
increased levels of E-cadherin and cleaved caspase-3, no 
evidence of full cavitation or mature lumen formation 
was found (Figure 4B). The loss of invasive potential 
we observed in vitro was reproduced in vivo using 4T1 
cells, which closely mimic tumor growth and metastatic 
spread of stage IV human breast cancer in BALB/c. 4T1 
cells were treated ex vivo for 14 days with Tat-SID, which 
resulted in no significant change in cell numbers compared 
to Tat-Scr control. However, when equal numbers of these 
cells were inoculated orthotopically as allografts into the 
inguinal mammary gland number 4 of BALB/c female 
mice, Tat-SID treated cells generated tumors that grew 
significantly slower than controls, resulting in a 4.2-fold 
reduction in mean tumor volume and 2.3-fold reduction in 
mean tumor mass after 20 days (Figures 4C and S6A). Ex 
vivo Tat-SID treatment of 4T1 cells also led to a dramatic 
reduction in the number and size of lung metastasis (a 
median value of 3 for 1 µM Tat-SID; 1 for 2.5 µM Tat-SID 
versus 23 for vehicle and 13 for Tat-Scr) (Figure 4D). In 
comparison to vehicle treated, decrease in lung metastasis 
was observed with Tat-Scr but it was not statistically 
significant. Similarly, tumor growth of MMTV-Myc cells 
treated ex vivo with Tat-SID was found to be impaired 2.1-
fold 12 days after injection (Figure S6B).
Blocking SIN3-PAH2 interactions reduces tumor-
initiating TNBC stem cells
Our results suggested that Tat-SID modulates 
transcriptional and epigenetic program governing EMT 
and CSC maintenance in TNBC (Figure 3, Figure 4, 
Table 1 and Tables S1-S6). We therefore analyzed Tat-
SID induced changes in the expression of established 
CSC markers as defined by increased ALDH activity and 
Table 1: List of genes involved in EMT that are downregulated in MDA-MB-231 cells treated with Tat-SID
Gene Entrez Name Log Ratio (Tat-SID/Tat-Scr)
CDH2 Cadherin 2, type 1, N-cadherin (neuronal) -1.480
EGR1 Early growth response 1 -1.050
FGF2 Fibroblast growth factor 2 (basic) -1.510
FGFR2 Fibroblast growth factor receptor 2 -2.040
FGFR4 Fibroblast growth factor receptor 4 -1.330
FOXC2 Forkhead box C2 (MFH-1, mesenchyme forkhead 1) -1.370
PIK3C2B Phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta -1.230
TWIST1 Twist basic helix-loop-helix transcription factor 1 -1.010
WNT10B Wingless-type MMTV integration site family, member 10B -1.050
WNT5A Wingless-type MMTV integration site family, member 5A -1.530
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a CD44high/CD24low/neg antigenic state [33-35]. Basal-B 
sub-type cell lines such as MDA-MB-231 have increased 
ALDH activity and display a CD44high/CD24low/neg antigen 
profile [36-38]. Tat-SID treatment significantly reduced 
the ALDH activity (12.5% ALDH+ cells versus 21.3% 
ALDH+ cells in controls, Figure 5A). Similar results were 
also obtained in mouse 4T1 cells (Figure S7). Tat-SID 
also altered the ratios of CD44 and CD24 double-positive 
cells, leading to an increase in cell populations defined 
by CD44low/CD24low/neg (16.0% versus 6.7% in controls, 
Figure 5B). Levels of another important breast CSC 
marker, CD49f [39, 40], were also downregulated (36% 
reduction, Figure 5C). Expression of NANOG, SOX2 and 
OCT4 proteins, hallmarks of stem cell pluripotency and 
self-renewal, were also downregulated in MDA-MB-231 
cells treated with Tat-SID (Figure 5D). This reduction in 
stem cell markers correlated with significantly impaired 
growth and a 2.5-fold reduction in tumorsphere formation 
(Figure 5E). Similarly, the number of mouse 4T1 
tumorspheres was reduced 4.5-fold in response to Tat-SID 
(Figure 5E).
Figure 3: Tat-SID reduces global promoter H3K4 trimethylation. A. Heatmap representing the correlation (Spearman) of 
the H3K4me3 ChIP signal between untreated (UT), 1 μM Tat-SID treated and 2.5 μM Tat-SID treated MDA-MB-231 cells. Unsupervised 
hierarchical clustering of samples is shown. B. Average H3K4me3 ChIP signal at all annotated TSS (-5Kb to +5Kb) in untreated and Tat-
SID treated MDA-MB-231 cells. C. Overlaid H3K4me3 ChIP signal (fold enrichment over input) at the TSS of CD44, ITGA6 and SNAI2 in 
untreated (light blue) and 2.5 μM Tat-SID treated (orange) MDA-MB-231 cells. Regions with significantly decreased H3K4me3 signal (FDR 
< 1 x 10-15) are underscored (dark blue bars). Overlapped regions are shown as green.
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PF1 modulates the stem-like traits of tumor-
initiating CSCs
Recent research has revealed that PF1 is highly 
expressed during chick neural crest EMT, recruiting Snail2 
and HDACs to specifically repress transcription of the 
adhesion molecule Cad6b (Cadherin6b) and E-cadherin 
[41]. Given that Tat-SID disrupted the binding between 
PAH2 domain of SIN3A and PF1 (Figure 1), we further 
investigated the role of PF1 function in modulation 
of EMT and CSC. MDA-MB-231 cells were stably 
transfected with PF1-shRNA or non-specific scrambled 
(Scr) shRNA (Figure 6A). Consistent with a role for PF1 
in the regulation of CDH1 expression, a 2.5-fold increase 
in CDH1 was observed after PF1 knockdown (Figure 6B). 
Further supporting our finding that suggests disruption of 
the SIN3A-PF1 interaction underpins the molecular and 
phenotypic changes observed with Tat-SID, we observed a 
2-fold reduction in 3D colony-forming potential and a 20-
fold reduction (3.4% versus 67.7%) in invasive colonies 
in cells transfected with PF1 shRNA compared to control 
(Figure 6C). PF1 knockdown was also accompanied by a 
1.5-fold reduction in the tumorsphere-forming ability of 
MDA-MB-231 cells (Figure 6D). Also consistent with Tat-
SID treatment, PF1 depletion significantly reduced mRNA 
and protein levels of NANOG, OCT4 and SOX2 (Figure 
7A-7C). Consistent with our ChIP-Seq results, knockdown 
Figure 4: Tat-SID impairs invasive morphogenesis and induces anti-tumor effects. A. Colony morphogenesis of MDA-
MB-231 cells treated with Tat-Scr or Tat-SID at the indicated concentrations. Cells were cultured in 3D matrigel for 10 days followed by 
staining of colonies with phalloidin (red) and DAPI (blue nuclear stain). Arrows indicate invasive projections. Scale bars: 25 µm (left), 
10 µm (right). B. MDA-MB-231 cells were treated with Tat-Scr or Tat-SID and cultured as described in (A). Colonies were stained with 
caspase-3 (green) and E-cadherin (red). Scale bars: 50 µm. C. Tumor progression in Balb/c mice (n = 5) inoculated with 4T1 cells treated 
with water, Tat-Scr (2.5 µM) or Tat-SID (1 µM and 2.5 µM) for 14 days, and tumor volume quantified at the indicated time points. Tat-Scr 
versus 1 µM Tat-SID day 20, ***, p = 0.0007; Tat-Scr versus 2.5 µM Tat-SID day 20, ***, p = 0.0003; p, unpaired t-test. D. Lungs from 
sacrificed animals in (C) (n = 5) were isolated and quantified for the number of metastasis observed. Left panel is quantification of number 
of metastatic foci observed on the surface of the lungs. Right panel is the image of lungs isolated from the sacrificed mice. Tat-Scr versus 
untreated, ns, p = 0.2107; Tat-Scr versus 1 µM Tat-SID, *, p = 0.0185; Tat-Scr versus 2.5 µM Tat-SID day 20, *, p = 0.0446; p, unpaired 
t-test. Error bars represent mean ± SD.
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of PF1 in MDA-MB-231 cells resulted in 5-fold, 2.7-fold 
and 3-fold reduction, respectively, in H3K4me3 enrichment 
at the CD44, ITGA6 and SNAI2 promoters (Figure 7D).
Supporting a role for PF1 in cancer stem cell 
maintenance and in agreement with Tat-SID data, PF1 
knockdown resulted in a 2.5-fold decrease in ALDH1 
positive cells (6.55% in Scr-shRNA versus 2.59% in PF1-
shRNA; Figure 8A). Moreover, the CD44low/CD24low/neg 
population was enriched 3-fold in cells transfected with 
PF1 shRNA compared with control (Figure 8B). Similarly, 
using a different shRNA construct, PF1 knockdown in 
mouse 4T1 cells (Figure 8C) led to fewer ALDH+ cells 
(Figure 8D) as well as increase in the proportion of cells 
with decreased expression of the breast cancer stem cell 
markers CD49f and CD29 (Figure 8E). In vivo, PF1 
knockdown in 4T1 cells generated tumors that grew 
significantly slower than scrambled control, resulting in 
a 3.5-fold reduction in mean tumor volume after 18 days 
(Figure 9A). We also found that knockdown of PF1 in 
4T1 cells resulted in a significant reduction in the number 
and size of lung metastasis 35 days after tumor removal 
(PF1 shRNA, median = 20 versus Scr shRNA, median = 
52) (Figure 9B and 9C). Furthermore, mice bearing PF1 
knockdown tumors displayed longer overall tumor-free 
survival compared to controls following tumor excision 
(Figure 9D). Despite the small sample size (n = 5), two 
mice in which PF1 knockdown tumors were excised 
showed no clinical disease symptoms and macroscopic 
Figure 5: Tat-SID induces decreased expression and activity of CSC markers in TNBC cells. A. ALDH1 activity in MDA-
MB-231 cells treated with 1 µM Tat-Scr (grey) or Tat-SID (red) for 72 h. Results are quantified as percentage of ALDH+ cells. Left panel 
is a graph showing the mean ALDH activity from three independent experiments. Right panel is plot from one representative experiment. 
*, p = 0.0395; p, unpaired t-test. B. FACS analysis showing changes in the CD44low/CD24low/neg population in MDA-MB-231 cells treated 
with 1 µM Tat-Scr (grey) or Tat-SID (red) for 72 h. Results are quantified as percentage of cell population. Left panel is a graph showing 
the mean value from three independent experiments. Right panel is plot from one representative experiment. *, p = 0.01; p, unpaired t-test. 
C. FACS analysis for CD49f positive cells in MDA-MB231 cells treated with 1 µM Tat-Scr (grey) or Tat-SID (red) for 72 h. Results are 
quantified as mean fluorescence intensity of CD49f positive cells. ***, p = 0.0002; p, one sample t-test. D. FACS analysis for NANOG, 
OCT4 and SOX2 staining in MDA-MB-231 cells treated with 1 µM Tat-Scr (grey) or Tat-SID (red) for 72 h. Result is quantified as mean 
fluorescence intensity from three independent experiments. NANOG, *, p = 0.0112; OCT4, *, p = 0.0157; SOX2, *, p = 0.0345; p, one 
sample t-test. E. Tumorsphere assay in MDA-MB-231 (red) and 4T1 cells (blue) treated with 1 µM Tat-Scr or 1 µM Tat-SID for 72 h. 
Results are quantified for number of tumorspheres. MDA-MB-231, ****, p < 0.0001; 4T1, *, p = 0.0239; p, unpaired t-test. Error bars 
represent mean ± SD (n = 3).
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lung metastases were not evident when these mice were 
electively sacrificed. Lastly, we performed an examination 
of the bone marrow for disseminated tumor cells (DTCs) 
that are associated with poor outcome in patients with 
metastatic breast cancer [42, 43]. In agreement with our 
prior work [15, 16] and results with activity of Tat-SID 
against dissemination of lung metastases, PF1 depletion 
in 4T1 cells also led to a significant 12-fold decrease in 
the number of bone marrow DTCs compared to control 
(Figure 9E), with DTCs isolated from mice bearing PF1 
knockdown tumors proliferating at a slower rate and with 
6.7-fold fewer cells per colony (Figure 9F).
DISCUSSION
In this study we show that Tat-SID disrupts 
interaction between the PAH2 domain of SIN3 and the 
PF1 chromatin regulator that is expressed from a locus 
amplified in breast cancer [17, 18]. Our results strongly 
suggest that this mechanism underlies the molecular 
and phenotypic effects arising from treatment with 
SID peptide, and this also applies to recently described 
small molecule mimetics of SID (avermectins) [16]. The 
prior identification of a complex containing chromatin-
modifying proteins, PF1, MRG15, EMSY and LID/
KDM5A, that was found to interact with SIN3 [20, 23-25, 
Figure 6: PF1 Knockdown inhibits the formation of invasive colonies and tumorspheres. A. Immunoblot analysis of 
PF1 expression in MDA-MB-231 cells in two independent PF1-shRNA transfection experiments (Lane 2 and 3) in comparison to Scr-
shRNA transfection (Lane 1). Numbers represent densitometric analysis of blotted protein bands. B. qRT-PCR for expression of CDH1 
mRNA in MDA-MB-231 cells stably transfected with Scr-shRNA (grey) or PF1-shRNA (red). ***, p = 0.0003; p, unpaired t-test. C. Left, 
quantification of the invasive (red) and non-invasive colonies (grey) formed by MDA-MB-231 cells stably transfected with Scr-shRNA or 
PF1-shRNA and cultured on basement membrane extract. Right, phase contrast images of the colonies formed. The arrows point to invasive 
projections typical of an invasive colony. Error bars represent mean ± SD (p = 2). Invasive cells, *, p = 0.0334; p, unpaired t-test. Scale bar: 
100 µm. D. Tumorsphere assay for PF1-shRNA (red) and Scr-shRNA (grey) transfected MDA-MB-231 cells. *, p = 0.015; p, one sample 
t-test, (n = 3). Error bars represent mean ± SD.
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44] led us to speculate that disruption of histone H3K4 
demethylase recruitment could be responsible for the 
dramatic increases in H3K4me3 at the CDH1 and ESR1 
promoters we observed previously upon exposure to SID 
peptide [15]. Recent reports suggesting a role for KDM5B 
in regulation of the EMT program in cancer stem cells [45, 
46] and interaction of KDM5B with EMSY [29], prompted 
us to investigate the SIN3A-KDM5B interaction.
While our finding that 3-days Tat-SID treatment led 
to a decrease in genome-wide H3K4me3 is in contrast to 
previously-reported increases in H3K4me3 at the CDH1 
and ESR1 promoters [15], it should be noted that the 
previous results were observed after a longer time period 
[15]. This suggests that re-expression of these genes 
precedes a large increase in H3K4me3, which may serve to 
“lock in” a permissive epigenetic state in response to SID 
treatment. Thus an increase in histone acetylation through 
prevention of recruitment of a deacetylase-containing 
complex may be the initial route for epigenetic remodeling 
in response to inhibition of PAH2 interactions. Our finding 
that H3K4me3 decreases in response to Tat-SID-mediated 
disruption of KDM5B is in agreement with recent studies 
in which KDM5B has been knocked down in embryonic 
stem cells [47] or breast cancer cell lines [30, 48], as well 
as in a mouse knockout model [49]. The mechanisms 
underpinning these results remain to be established but 
possibilities include a role for KDM5B in fine-tuning 
epigenetic regulation of genes. Furthermore, the effect on 
individual genes of blocking interactions between SIN3 
and KDM5B may be difficult to predict given that recent 
research has demonstrated that ‘co-repressor complexes’ 
including SIN3 can function in transcriptional activation 
as well as repression [50]. This may also be the case 
with KDM5B as its Drosophila homolog, Lid, has been 
shown to activate transcription by inhibiting the histone 
deacetylase activity of Rpd3 in PF1-MRG15 complex 
Figure 7: PF1 regulates the expression of TNBC stem cell genes. A. qRT-PCR for expression of NANOG (grey), OCT4 (red) 
and SOX2 (blue) in MDA-MB-231 cells transfected with PF1-shRNA relative to Scr-shRNA control. NANOG, **, p = 0.0042; OCT4, **, 
p = 0.0019; SOX2, ***, p = 0.0001; p, unpaired t-test, (n = 3). B. FACS analysis of NANOG, OCT4 and SOX2 proteins in MDA-MB-231 
cells transfected with Scr-shRNA (grey) or PF1-shRNA (red). Results are quantified as mean fluorescence intensity from three independent 
experiments. Error bars represent mean ± SD (n = 3). C. Confocal images of MDA-MB-231 cells stably transfected with Scr-shRNA or 
PF1-shRNA and stained with antibodies against NANOG (red), OCT4 (red) and SOX2 (green). Scale bar: 50 µm. D. ChIP analysis of 
CD44, ITGA6 and SNAI2 gene promoters for H3K4me3 in MDA-MB-231 cells transfected with Scr-shRNA (grey) or PF1-shRNA (red). 
CD44, **, p = 0.0023; ITGA6, *, p = 0.0205; SNAI2, *, p = 0.0120; p, unpaired t-test, (n = 3). Error bars represent mean ± SD.
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[51]. Further characterization of the consequences of 
PAH2 inhibition should also focus on whether this impacts 
function of the breast cancer oncoprotein EMSY, which 
has been shown to interact with PF1 and, more recently, 
KDM5B to repress expression of the anti-metastatic 
microRNA miR-31 [25, 29].
The most important finding of this study is the 
identification of PF1 as a therapeutically targetable factor 
required for maintenance of EMT and the CSC phenotype. 
Treatment with both SID peptide and avermectins [16] 
targets multiple key genes in the EMT pathway, including 
TGFB1, and it is noteworthy that inhibition of TGFβ 
activity has been associated with loss of KDM5B in basal-
like breast cancer cells [30]. Another PAH2-interacting 
protein, TIEG1 has also been shown to play a role in the 
TGFβ/SMAD signal transduction pathway [52, 53] and 
disruption of this interaction also warrants investigation. 
Passage through EMT contributes to generation and 
maintenance of tumor-initiating CSCs [5] and genome-
wide transcriptional profiling of several breast cancer 
cell lines has uncovered a relationship between EMT and 
breast CSCs (BCSCs) [33, 54, 55]. Here, basal-B subgroup 
cell lines (such as MDA-MB-231 used in this study) were 
found to express an EMT signature and are thus enriched 
with cells that have undergone at least a partial EMT 
and acquisition of CSC properties such as expression of 
Figure 8: PF1 maintains a stem cell phenotype in TNBC. A. ALDH1 activity in MDA-MB-231 cells transfected with Scr 
(grey) or PF1-shRNA (red). Results are quantified as percentage of ALDH+ cells. Left panel is graph showing the mean value from three 
independent experiments and the right panel is plot from one representative experiment. ****, p < 0.0001; p, unpaired t-test, (n = 3). B. 
FACS analysis showing changes in the CD44low/CD24low/neg population in MDA-MB-231 cells transfected with Scr-shRNA (grey) or PF1-
shRNA (red). Results are quantified based on the percentage of cells. Left panel is graph showing the mean value from three independent 
experiments and the right panel is plot from one representative experiment. *, p = 0.0110; p, unpaired t-test, (n = 3). C. Immunoblot 
analysis of PF1 expression in 4T1 cells stably transfected with Scr-shRNA or PF1-shRNA and selected with 2 (Lane 2) or 3 μg/ml (Lane 
3), of puromycin. Numbers represent the densitometric analysis of the blot. Cells selected with 3 μg/ml puromycin (Lane 3) were used for 
further experiments. D. ALDH1 activity in 4T1 cells transfected with Scr (grey) or PF1 shRNA (red). Results are quantified as percentage of 
ALDH+ cells. ***, p = 0.0008; p, unpaired t-test, (n = 3). E. FACS analysis showing changes in the CD29low/CD49flow/neg population in 4T1 
cells transfected with Scr (grey) or PF1 shRNA (red). Results are quantified based on the percentage of cells. ***, p = 0.0008; p, unpaired 
t-test, (n = 3). Error bars represent mean ± SD.
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mesenchymal genes and enhanced invasiveness. These 
include cells with increased ALDH activity and CD44high/
CD24low/neg antigenic state [33-35]. We observed that both 
Tat-SID treatment and PF1 knockdown decreased ALDH 
activity and also shifted the population towards a CD44low/
CD24+ composition that is associated with a luminal 
phenotype [33, 55-57]. Our results also show down-
regulation of other breast CSC-associated genes/markers 
like CD49f, ALDH, NANOG, OCT4, and SOX2 in both 
Tat-SID treated and PF1 knockdown cells. Of these, the 
promoters of CD49f and CD44 also showed a decrease 
in the H3K4me3 mark. Thus, our results have identified 
Figure 9: PF1 knockdown inhibits primary tumor growth and disseminated metastatic disease in vivo. A. Tumor 
progression in Balb/c mice (n = 10) inoculated with 4T1 cells transfected with Scr-shRNA (black) or PF1-shRNA (red). Tumor volumes 
were quantitated at the indicated time points. Day 18, ***, p = 0.0001; p, unpaired t-test. Primary tumors were resected, and after 35 days 
five mice were sacrificed for analysis of lung metastasis (described in panel B). The remaining five  mice were analysed for survival (panel 
D) and the presence of disseminated tumor cells (DTCs) in bone marrow (panel E and F). B. Lungs from sacrificed Balb/c mice inoculated 
as described in (A) were isolated and quantified for the number of metastasis observed. *, p = 0.0159; p, unpaired t-test, (n = 5). C. Images 
of lung metastasis observed in Balb/c mice sacrificed and isolated in (B). D. Kaplan-Meier analysis following removal of primary tumors 
in Balb/c mice from (A) (n = 5). E. Quantification of the disseminated 4T1 tumor cells isolated from the bone marrow of sacrificed animals 
from (D). *, p = 0.0139; p, unpaired t-test. F. Left, graph showing the average number of cells per colony formed by disseminated 4T1 
tumor cells from bone marrow of Balb/c mice from (D). ***, p = 0.0006; p, unpaired t-test. Right, phase contrast images of the colonies 
formed by the disseminated tumor cells isolated from the bone marrow of mice from (D). Scale bar: 100 µm. Error bars represent mean ± 
SD.
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PF1 as a critical factor for the breast CSC phenotype, 
which is an important step forward in understanding 
the mechanisms responsible for the maintenance of this 
cell population. The recent finding that PF1 is highly 
expressed during chick neural crest EMT, recruiting Snail2 
and HDACs to specifically repress transcription of the 
adhesion molecule Cad6b (Cadherin6b) and E-cadherin 
[41], strongly suggests that its biological activities in 
TNBC be investigated further. Expression of SNAIL is 
an indicator of poor prognosis in breast cancer. This is 
linked to repression of CDH1 and induction of EMT that 
occurs through recruitment of SIN3A and HDACs by 
SNAIL to E-boxes contained in the CDH1 promoter [59-
61]. Whether SNAIL also recruits a SIN3A-PF1-MRG15-
KDM5B complex to repress CDH1 expression and induce 
EMT remains to be established.
Although the SIN3A PAH2-interacting SID of 
PF1 possesses structural and sequence homology with 
MAD SID, the interaction is 10-fold lower in affinity 
compared with the prototypic SIN3-MAD interaction 
[31]. Therefore, the use of small molecules based on in 
silico modeling of the MAD-SID sequence to prevent 
recruitment of the PF1-containing complexes represents 
a new and potentially clinically effective therapeutic 
strategy. While it cannot be ruled out that the effects of 
SID treatment act through inhibiting the interaction of 
additional PAH2-binding proteins with SIN3, the finding 
that PF1 knockdown phenocopied Tat-SID suggests that it 
is the principal target. In light of this, it will be important 
to determine whether promoters that are epigenetically 
modulated by PF1 depletion are direct or downstream 
targets. The number of partner proteins thus far identified 
for PF1 is relatively small (http://thebiogrid.org) but 
the identification of retinoblastoma binding protein 7 
(RBBP7) and BRCA1 suggest additional potential roles 
for PF1 including in DNA repair.
Our results strongly point to gene- and pathway-
specific modulation of epigenetic markers and 
transcription in response to Tat-SID. This results in 
dramatic in vitro phenotypic changes characterized by 
partial differentiation, reversal of EMT and decreased 
CSCs that translate into significantly reduced metastatic 
disease dissemination in vivo. Selective inhibition of 
SIN3A function using SID decoy leads to clinically 
relevant epigenetic reprogramming in TNBC and 
defines the SIN3A-PF1 protein interaction as a bone fide 
therapeutic target.
MATERIALS AND METHODS
Cell culture, plasmids and transfections
The mouse metastatic mammary 4T1 tumor cell 
line (Cat# CRL-2539) and human MDA-MB-231 breast 
adenocarcinoma cell line (Cat# HTB-26) were purchased 
from the American Type Culture Collection (ATCC). 
The mouse mammary tumor MMTV-Myc cell line 
has been previously reported [62, 63]. Cell lines were 
authenticated by short tandem repeat (STR) profiling in 
accordance with the standard ASN-0002-2011 in April 
2015 (DDC Medical). 4T1 cells were maintained in RPMI 
supplemented with 10% fetal bovine serum (FBS) and 1% 
Antibiotic-Antimycotic solution (Invitrogen). The MDA-
MB-231 cell line was maintained in DMEM supplemented 
with 10% FBS, 1% GlutaMAX (Invitrogen), 10mM 
HEPES, 1mM sodium pyruvate, non-essential amino 
acids and 1% antibiotic-antimycotic solution. MMTV-Myc 
cells were cultured in DMEM/F12 medium supplemented 
with 5% FBS, 1% GlutaMAX, 10mM HEPES, and 1% 
antibiotic-antimycotic solution. Stable knockdown of 
PF1 in MDA-MB-231 was performed with pLKO-
PF1 shRNA (clone# TRCN0000015704), which was a 
kind gift from the laboratory of Gregory David (NYU 
School of Medicine, NY, USA) [44]. A second pLKO-
PF1 shRNA construct (clone# TRCN0000084422, Sigma 
Aldrich) was used for stable knockdown in mouse 4T1 
cells. Stable transfections were performed with 1 µg of 
DNA using TurboFect (ThermoScientific) according to the 
manufacturer’s recommendations.
Peptides
MAD-SID peptide (Tat-SID: YGRKKRRQGGG-
VRMNIQMLLEAADYLERRER) with or 




and PF1 scrambled 
(YGRKKRRQGGGRLFMQLELRATPAEAPINQR) 
were synthesized to a purity level of 95% as assessed 
by analytical reversed phase-high performance liquid 
chromatography (BioSynthesis, Inc).
Peptide internalization assay
Sub-confluent cultures of MDA-MB-231 cells were 
treated with FITC-conjugated Tat-SID (1 µM) for 2 h and 
24 h. For flow cytometry the cells were trypsinized and 
resuspended in 1% BSA-PBS solution and analyzed using 
flow cytometer BDCanto (BD BioSciences). For confocal 
imaging cells were washed with PBS and mounted using 
Prolonged Gold Antifade with DAPI (Molecular Probes) 
and analyzed using Leica SP5 confocal microscope.
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Purification of the PAH2 domain of SIN3A
The PAH2 domain of mSin3A was overexpressed in 
the E. coli BL21 (DE3) codon plus RIL strain (Stratagene) 
by addition of 1 mM isopropyl-1-thio-D-galactopyranoside 
and incubation overnight at 15°C. Harvested cells were re-
suspended in 50 mM sodium phosphate buffer, pH 7.4, 
supplemented with 500 mM sodium chloride, 5% glycerol, 
and 0.1% Igepal CA-630 and lysed using a microfluidizer 
(Micro- fluidics) at 20,000 psi. After clarification of the 
crude extract by high-speed centrifugation, the lysate 
was loaded onto a 5 ml HiTrap chelating column (GE 
Healthcare) charged with Ni2+. The column was washed 
and the protein was eluted with 30 mM HEPES pH 7.4, 
250 mM sodium chloride, and 250 mM imidazole. The 
protein was next purified on a Superdex75 column (GE 
Healthcare) equilibrated with 20 mM Tris-HCl buffer, pH 
8.0, and 150 mM sodium chloride. Fractions containing 
the pure protein were combined and concentrated with 3 
kDa MWCO centrifugal filters (Amicon).
Competition assay for pSID peptide binding 
affinity
The binding affinity of pSID for SIN3A was 
assessed in a fluorescence anisotropy competition assay 
using a fluorescein isothiocyanate-labeled Mad1 peptide 
as an assay probe. Competition experiments were 
performed with 70 nM purified mSin3A PAH2 domain and 
10 nM fluorescent probe and increasing concentrations of 
unlabeled competing pSID in a PBS buffer (pH 7.4) with 
0.01% BSA in total volume of 40 µL. Measurements were 
obtained after a 1 h incubation of the fluorescent ligand 
and the protein at 25oC with a Safire 2 microplate reader 
(Tecan). Assuming a one-site competitive binding model, 
the data was fit using Prism software.
Immunofluorescence
MDA-MB-231 cells were cultured on 8 
chambered wells (BD Biosciences) and fixed with 4% 
paraformaldehyde/PBS for 15 min at room temperature. 
For 3D cultures cells were seeded (3 × 103/well) in 
quadruplicate onto Matrigel (BD Biosciences) or Cultrex 
basement membrane extracts (Trevigen) in 8-well culture 
slides to prepare three-dimensional cultures as described 
earlier [64]. The media was changed every 48 h for 8 
consecutive days. Colony morphology was determined 
by phase-contrast microscopy. For immunostaining, cells 
were permeabilized with 0.5% Triton X-100/PBS and 
blocked with 10% normal goat serum (Invitrogen) in PBS 
for 1 h. Primary antibodies were incubated overnight at 
4ºC in blocking buffer and washed 3 times with washing 
buffer (0.05% Triton X-100/PBS) and once with PBS. 
Secondary antibodies (dilution 1:200 in 1% normal goat 
serum/PBS) were added for 1 h and then washed. The 
samples were then mounted with ProLong Gold antifade 
reagent with DAPI (Molecular Probes/Invitrogen, CA), 
following the manufacturer instructions. All incubations 
and washes were done at 4 or 25ºC as required. Confocal 
microscopy was performed using a Leica SP5 confocal 
microscope at the Shared Instrumentation facility of 
department of Hematology at Mount Sinai School of 
Medicine, NY.
Proximity ligation assay
MDA-MB-231 cells plated onto coverslips in 12 
well plates with or without Tat-SID treatment were stained 
with monoclonal SIN3A (sc-5299) 1:100 and polyclonal 
KDM5B (ab50958) 1:1000 following the Duolink 
protocol according to the manufacturer’s instructions 
(Olink Bioscience) except utilizing 1% BSA in PBS as a 
blocking reagent and carrying out initial washes in PBS. 
Cells were counterstained in To-pro-3-iodide in PBS, 3x5 
min washes at RT and mounted in Vectashield mounting 
medium (vector labs). Images were collected on a Zeiss 
LSM700 confocal microscope and the Duolink software 
was utilized to quantitate the signals.
Co-IP
MDA-MB 231 cells were treated with 1 µM 
Tat-SID peptide. Nuclear Extracts were used for 
immunoprecipitation (IP) with SIN3A (Abcam, ab3479) 
and KDM5B (Abcam, ab27689) antibodies using IP kit 
from Thermo Scientific and probed with SIN3A, KDM5B, 
PF1 or MRG15 antibody by immunoblot analysis.
Tumorspheres assay
Between 1 to 5.0 x103 MDA-MB-231 or 4T1 or 
cells treated with 1µM Tat-SID or Tat-Scr for 72 h, were 
plated in ultra low adhesion 6-well plates (Corning, 
Corning, NY) and incubated in serum-free F12/DMEM 
(Cellgro) supplemented with 20ng/ml EGF, 0.5% Matrigel 
and 1:50 B27 Supplement (Invitrogen) for 8-10 days at 
37°C in a humidified atmosphere of 5% CO2. The number 
of tumorspheres per well (triplicates) were counted.
Quantification of cancer stem cell markers
For aldehyde dehydrogenase assay, cells were 
dissociated with PBS-EDTA and tested for ALDH activity 
(2 × 105 cells/sample), using the Aldefluor assay (Aldegen) 
according to the manufacturer’s instructions. For CD44 
and CD24 antigens, cells were dissociated with Accutase, 
washed with PBS and incubated with PE-conjugated anti-
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CD24 and APC-conjugated anti-CD44 antibodies (BD 
Biosciences) for 40 minutes in ice. For quantification of 
NANOG, OCT4 and SOX2 dissociated cells were fixed 
with 1% paraformaldehyde (15 min at RT), permeabilized 
with 0.5% TritonX100 (10 min at RT) and incubated with 
1:100 diluted antibodies against NANOG, OCT4 and 
SOX2 (Cell Signaling) for 1 h at room temperature. The 
cells were then washed and incubated with fluorophore-
conjugated secondary antibodies Abcam). FACS analysis 
was carried out using a FACScanto flow cytometer, DIVA 
software program for acquisition (BD Biosciences) and 
FlowJo (Treestar.) software for analysis.
Quantitative real-time PCR
RNA was isolated using RNeasy Plus Mini Kit 
(Qiagen), and cDNA was prepared using Superscript First-
Strand Synthesis System for RT-PCR Kit (Invitrogen) 
or iTaqScript (Bio-Rad), all following manufacturers’ 
instructions. Quantitative real-time PCR was performed 
using manufacturers’ instructions for QuantiTect SYBR 
Green PCR (Qiagen) or iTaq Universal SYBR Green 
Supermix (Bio-Rad) kits on Opticon or CFX96 machines 
(Bio-Rad) with annealing temperature 54 °C with 50-
250 ng cDNA per reaction. For determination of gene 
expression the “delta-delta Ct method” was used relatively 
to RPL30 housekeeping genes. PCR primers are listed in 
supplementary Table S8.
Affymetrix expression analysis
Sub-confluent cultures of MDA-MB-231 cells were 
treated with 1 µM scrambled (Tat-Scr) or SID peptide 
(Tat-SID) for 24 h. Total RNA was isolated using the ZR 
RNA MiniPrep Kit (Zymo Research). The concentration 
and quality of the total RNA was assessed on an Agilent 
2100 BioAnalyzer (Agilent Technologies). All samples 
were normalized to 200ng and processed according 
to standard Affymetrix protocols using GeneChip WT 
Terminal Labeling and Controls Kit (Affymetrix) and 
WT Expression Kit (Ambion). The quality and quantity 
of labeled cRNA was checked and 750 ng of labeled 
cRNA were hybridized to a GeneChip Human Gene 1.0 
ST Arrays using GeneChip Hybridization, Wash, and Stain 
Kit (Affymetrix). The arrays were scanned on a GeneChip 
Scanner 3000 7G. Affymetrix array data were analyzed 
by Chipinspector 2.1 (Genomatix). Transcripts were 
considered significantly regulated if at least 3 significant 
probes mapped to them and the log2 fold change of the 
transcript calculated from these probes was above 1 
or below -1. For all subsequent analyses, we used the 
median expression values of two independent biological 
replicates. Replicates were combined exhaustively, i.e. 
mean fold changes were calculated by comparing each 
replicate from the treatment group to each replicate from 
the control group. Log2 fold change values for genes were 
calculated as the average of the log2 fold change values of 
the corresponding significantly regulated transcripts and 
a False Discovery Rate (FDR) was set as 5%. Expression 
microarray analysis was performed according to Minimum 
Information About a Microarray Gene Experiment 
(MIAME) guidelines and data have deposited on the 
Gene Expression Ontology (GEO) database with the 
series accession number GSE73278. The GEO superseries 
accession number for this study is GSE73871.
Pathway and network analysis
Ingenuity Pathway Analysis (IPA) software 
(www.ingenuity.com) was used to identify significantly 
overrepresented pathways, cellular functions and upstream 
transcription factor analysis in the list of identified 
proteins. The Tat-SID versus Tat-Scr peptide expression 
data were imported into IPA and filtered on 2-fold change 
before a core analysis was performed to identify the most 
significantly regulated proteins and associated cellular 
functions.
ChIP-Seq
Native ChIP-seq for H3K4me3 (Abcam, ab1012) 
was performed in untreated, 1 μM and 2.5 μM Tat-SID 
treated MDA-MB-231 cells as previously described [65]. 
Input DNA was used as control for the background. High 
throughput sequencing on all samples was performed 
using Illumina HiSeq 2500 with single-end sequencing of 
100nt (Mount Sinai Genomic Core Facility). Sequencing 
reads were quality checked by FastQC (version 0.10.0) 
and NGS-QC generator (version 1.5.1) [66] prior to 
analysis. Summary of ChIP QC is shown in Table 
S9. Sequence reads were then aligned to the Genome 
Reference Consortium Human Build 37 genome (hg19) 
with Bowtie (version 1.0.0) [67] using the following 
parameters: seed length (l) = 70 bp, maximum mismatch 
(n) = 2, suppression (m) = 20, and reported alignments 
(k) = 1. MACS2 program (version 2.1.0) [68] was used to 
generate Bedgraph files that show fold change enrichment 
of ChIP over input. Bedgraph files were then converted 
into BigWig files by BedClip program and uploaded onto 
UCSC genome browser for visualization and plotting. 
SICER-df program [69] was used to reveal significantly 
changed peaks between the untreated and Tat-SID treated 
MDA-MB-231 cells using the following parameters. 
For H3K4me3: window size = 50bp, gap size = 400bp, 
island calling = FDR<1x10-4, UT versus Tat-SID = 
FDR<1x10-8. Genes with significant histone modification 
changes were determined by intersecting significantly 
changed peaks of H3K4me3 ChIP (by SICER-df) to ±3 
Kb and ±10 kb TSS of all RefSeq genes, respectively, 
using Bedtools. Regions and genes with significant ChIP 
Oncotarget34102www.impactjournals.com/oncotarget
signal changes after Tat-SID treatment are summarized 
in Table S7. TSS analyses were performed using the 
SitePro tool from Cistrome (http://cistrome.org) [70]. 
The bed files containing genomic positions around TSS 
were generated using RefSeq gene annotation downloaded 
from UCSC Genome Browser (http://genome.ucsc.edu). 
Only the longest isoform of each gene was used to prevent 
double plotting of the same genomic region. Hierarchical 
clustering and correlation heatmap between each ChIP 
samples were generated with a 100 bp window and 
Spearman correlation using bamCorrelate function from 
deepTools program. Histone modification snapshots were 
generated using UCSC Genome Browser. Chi-Square test 
from GraphPad program (http://graphpad.com/quickcalcs/
chisquared1.cfm) was used to calculate the p value of 
KDM5B binding enrichment at H3K4me3 down genes 
after Tat-SID treatment. ChIP-Seq data have deposited 
on the Gene Expression Ontology (GEO) database with 
accession number GSE73869. The GEO superseries 
accession number for this study is GSE73871.
Chromatin immunoprecipitation (ChIP)
Native ChIP for H3K4me3 (Abcam, ab1012) 
was performed in MDA-MB-231 cells that were 
either untreated, treated with 1 µM or 2.5 µM Tat-
SID, or transfected with Scr-shRNA or PF1-shRNA 
as previously described [65]. Input DNA was used as 
control for the background. DNA obtained from input 
or immunoprecipitated DNA was analyzed by real-time 
PCR using primers mapping to the CD44, ITGA6 and 
SNAI2 promoter regions. Percent Input method was 
used for analysis. The following PCR primers were 









4T1 cells were treated for 14 days with water, Tat-
Scr (2.5 µM) or Tat-SID (1 & 2.5 µM) and then inoculated 
orthotopically in the inguinal mammary gland of Balb/c 
mice (n = 5). The mice were fed ad libitum and did not 
receive peptide treatment. Tumor volumes were calculated 
as ellipsoids (Dxd2/2) by measuring the main diameter 
(D) and the smaller diameter (d) and plotted versus time 
(days). The experiment was stopped when tumors in the 
control group reached ~500 mm3, then, the mice were 
sacrificed, tumors were isolated for weight and lungs were 
isolated for metastatic foci analysis. Similar experiment 
was also performed using MMTV-Myc cells. In another 
set of experiments 4T1 cells stably transfected with Scr-
shRNA or PF1-shRNA were inoculated in interscapular 
space of Balb/c mice (n = 10). Tumors were surgically 
removed when the Scr-shRNA group reached 500 mm3. 
Tumor-free survival was calculated from Kaplan-Meier 
curves, and statistical significance was determined using 
the log-rank test for survival and the t-test for tumor 
growth. Metastatic dissemination was evaluated by 
dissecting the lungs from sacrificed mice and inspecting 
the Bouin-fixed (Sigma) lung surface for lesions using 
a stereoscope (Nikon SMZ800 stereoscope X3 to X5). 
For measuring the disseminated tumor cells in the bone 
marrow (BM) aspirates were collected from the bone 
marrow from the femurs by flushing BM with PBS plus 2X 
antibiotic/antimycotic (A-A) solution (Life Technologies). 
Red blood cells were lysed for 3 min with red cell lysis 
buffer (Sigma). BM cells were recovered by centrifugation 
(1,200 x g for 3 min) at 4ºC, and re-suspended in 20 ml 
of culture medium with 2x A-A and 60 µM 6-thioguanine 
as previously described [71]. Single-cell suspensions were 
plated in 150 mm plated pre-coated with collagen type 1 
(collagen-1 coating solution 66 µg/ml in PBS). After 24 h 
plates, attached cells were washed three times with PBS 
and fresh medium containing 6-thioguanine added. After 
6 days, the number of colonies formed (each originating 
from a single tumor cell) were counted to evaluate the 
number of disseminated tumor cells (DTCs). To evaluate 
DTC proliferation, the number of cells per colony were 
counted using ImageJ software.
Statistical analyses
Statistical analyses were performed with GraphPad 
Prism software (version 5.0). The experiments were 
conducted with at least three independent experiments 
unless otherwise mentioned. Where shown, p values were 
calculated using the unpaired Student’s t-test, Mann-
Whitney or one-way ANOVA as indicated.
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